ACAD
What one share of Acadia Pharmaceuticals holds
Pharmaceutical Preparations
We are a biopharmaceutical company focused on turning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare disease communities around the world.
Acadia Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $6.61 |
|---|---|
| Profit | $2.21 |
| Capex (buildings and equipment) | $0.09 |
| Free cash flow | $0.85 |
| Cash and investments | $2.24 |
| Book value | $7.59 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2009 | — | −$1.20 | — | −$0.37 | — | $0.32 |
| 2010 | — | $0.39 | — | −$0.28 | — | $0.75 |
| 2011 | — | −$0.44 | $0.00 | −$0.38 | — | $0.44 |
| 2012 | — | −$0.38 | — | −$0.39 | — | $1.16 |
| 2013 | — | −$0.44 | $0.01 | −$0.38 | — | $2.00 |
| 2014 | — | −$0.95 | $0.00 | −$0.69 | — | $3.09 |
| 2015 | — | −$1.63 | $0.02 | −$1.23 | — | $1.96 |
| 2016 | $0.15 | −$2.34 | $0.01 | −$1.81 | — | $4.27 |
| 2017 | $1.02 | −$2.36 | $0.01 | −$1.78 | — | $2.69 |
| 2018 | $1.77 | −$1.94 | $0.02 | −$1.34 | — | $3.33 |
| 2019 | $2.30 | −$1.60 | $0.01 | −$1.03 | — | $4.50 |
| 2020 | $2.81 | −$1.79 | $0.05 | −$0.91 | — | $3.93 |
| 2021 | $3.02 | −$1.05 | $0.01 | −$0.79 | — | $3.36 |
| 2022 | $3.20 | −$1.34 | $0.00 | −$0.71 | — | $2.47 |
| 2023 | $4.43 | −$0.37 | $0.00 | $0.10 | — | $2.62 |
| 2024 | $5.76 | $1.36 | $0.00 | $0.94 | — | $4.40 |
| 2025 | $6.31 | $2.30 | $0.03 | $0.62 | — | $7.21 |